### ðŸ«  Valvular Heart Disease: Chronic Mitral Regurgitation Diagnosis

#### âœ… True Statements
1. **Chronic mitral regurgitation (MR)** produces a **diminished first heart sound (S1)** and a **holosystolic murmur that obscures the second heart sound (S2)** on cardiac auscultation.  
2. **Left atrial enlargement** secondary to **chronic mitral regurgitation** can be identified on an **electrocardiogram (ECG)** by a **widened P wave â‰¥120â€¯ms with an Mâ€‘shaped or notched morphology in limb leads I, II, or aVL**, or by a **biphasic P wave with a deep terminal negative component in lead V1**.  
3. **Left ventricular hypertrophy (LVH)** due to chronic volume overload from **chronic mitral regurgitation** is suggested on ECG when the **Sokolowâ€‘Lyon voltage criterion** is met (depth of the S wave in lead V1 plus height of the R wave in lead V5 or V6 **>35â€¯mm**).  
4. **Transthoracic echocardiography (TTE)** is the definitive test to **confirm and quantify chronic mitral regurgitation** suspected on physical examination and ECG.

#### ðŸ’¬ Extra
1. The holosystolic murmur of chronic MR originates at the mitral valve throughout systole and radiates to the axilla.  
2. Pâ€‘wave morphology changes reflect prolonged left atrial depolarization caused by chamber enlargement.  
3. LVH in chronic MR develops from longâ€‘standing volume overload rather than pressure overload.  
4. Echocardiography assesses mitral valve anatomy, regurgitant volume, regurgitant fraction, and leftâ€‘sided chamber dimensions.

#### ðŸ”· Tags
#Cardiology #AmbulatoryCare #ValvularHeartDisease #MitralRegurgitation #PhysicalExam #ECG #LeftAtrialEnlargement #LeftVentricularHypertrophy

#### ðŸ“™ Reference
MKSAPÂ 19: Cardiovascular MedicineÂ â€” Mitral Valve Disease, Chronic Mitral Regurgitation.

#### ðŸ†” Question ID
CVVDX24039

#### ðŸ•’ Last Updated
JanuaryÂ 2025

---

#### ðŸ“– Related Text
MKSAP 19: Cardiovascular Medicine â€” Valvular Heart Disease, Clinical Presentation and Evaluation of Mitral Regurgitation

---

### ðŸ“˜ Related Text Derivations

#### âœ… True Statements
1. **Mitral regurgitation (MR)** may arise from dysfunction of any component of the **mitral valve apparatus**â€”the annulus, leaflets, chordae tendineae, papillary muscles, or leftâ€‘ventricular (LV) free wall.  
2. **Primary MR** is most often due to **myxomatous degeneration causing mitralâ€‘valve prolapse**; valve tissue itself is structurally abnormal.  
3. **Secondary (functional) MR** is produced by **LV remodeling with papillaryâ€‘muscle displacement and leaflet tethering**, despite a structurally normal valve.  
4. **Acute severe MR** may present with a **softer systolic murmur and a small colorâ€‘Doppler jet** because LVâ€“leftâ€‘atrial (LA) pressures rapidly equalize during systole.  
5. **Chronic MR** induces progressive **volume overload**, leading to **eccentric LV dilation, LA hypertension, pulmonary hypertension, and eventual rightâ€‘ventricular (RV) failure**.  
6. On physical examination, **chronic MR** produces a **blowing holosystolic apical murmur** that may be **preceded by midsystolic clicks** when **mitralâ€‘valve prolapse** is present.  
7. **Transthoracic echocardiography (TTE)** is the firstâ€‘line modality to **quantify MR severity**; findings of **leaflet prolapse, flail segments, or ruptured chordae** indicate primary (degenerative) disease.  
8. **Severe primary MR** is defined by **effective regurgitant orifice area (EROA) â‰¥â€¯0.40â€¯cmÂ², regurgitant volume â‰¥â€¯60â€¯mL, or venaâ€‘contracta width â‰¥â€¯0.7â€¯cm**.  
9. When **TTE findings are inconclusive or discordant with clinical suspicion**, further evaluation with **transesophageal echocardiography (TEE)** or **cardiac magneticâ€‘resonance (CMR) imaging** is recommended.  
10. The **ACC/AHA valvularâ€‘heartâ€‘disease staging system** classifies lesions from **stageÂ A (at risk)** to **stageÂ D (symptomatic severe disease)** to guide surveillance and intervention timing.  
11. In **mild aortic stenosis** (V<sub>max</sub> 2.0â€“2.9â€¯m/s), repeat **echocardiography everyÂ 3â€“5â€¯years** is appropriate.  
12. In **moderate aortic stenosis** (V<sub>max</sub> 3.0â€“3.9â€¯m/s or mean gradient 20â€“39â€¯mmâ€¯Hg), **echocardiography everyÂ 1â€“2â€¯years** is advised.  
13. Asymptomatic patients with **severe aortic stenosis** (stageÂ C1: V<sub>max</sub>Â â‰¥â€¯4â€¯m/s, mean gradientÂ â‰¥â€¯40â€¯mmâ€¯Hg, or aorticâ€‘valve areaâ€¯â‰¤â€¯1.0â€¯cmÂ²) should have **clinical evaluation yearly** and **echocardiography everyÂ 6â€“12â€¯months**; the same schedule applies to **very severe stenosis** (V<sub>max</sub>Â â‰¥â€¯5â€¯m/s).  
14. For **aortic regurgitation (AR)**, **echocardiography everyÂ 3â€“5â€¯years** for mild AR, **1â€“2â€¯years** for moderate AR, and **6â€“12â€¯months** for severe AR (or sooner if the LV is dilating) is recommended.  
15. In **mitral stenosis (MS)**, **echocardiography everyÂ 3â€“5â€¯years** is appropriate for mildâ€‘toâ€‘moderate MS (mitralâ€‘valve areaâ€¯>â€¯1.5â€¯cmÂ²), whereas **severe MS** (areaâ€¯1.0â€“1.5â€¯cmÂ²) requires imaging **everyÂ 1â€“2â€¯years** and **annual** studies when the **valve areaâ€¯<â€¯1.0â€¯cmÂ²**.  
16. For **mitral regurgitation**, followâ€‘up **echocardiography everyÂ 3â€“5â€¯years** (mild), **1â€“2â€¯years** (moderate), and **6â€“12â€¯months** (severe), with **more frequent imaging if the LV is dilating**, is recommended.

#### ðŸ’¬ Extra
1. Anatomic disruption of any element of the mitral apparatus can impair leaflet coaptation and create regurgitation.  
2. Myxomatous degeneration leads to leaflet redundancy and chordal elongation, predisposing to prolapse.  
3. LV dilation after myocardial infarction or cardiomyopathy displaces papillary muscles, tethering leaflets outward.  
4. Rapid LVâ€“LA pressure equalization in acute MR limits the driving gradient for a loud murmur or large Doppler jet.  
5. Chronic volume overload causes eccentric LV hypertrophy, LA enlargement, and secondary pulmonaryâ€‘vascular changes.  
6. Murmur intensity and timing vary with loading conditions and leaflet motion; standing may accentuate clicks in prolapse.  
7. Detailed echocardiographic phenotype guides decisions about surgical repair versus replacement in degenerative MR.  
8. Quantitative Doppler thresholds (EROA, regurgitant volume, vena contracta) are reproducible measures of MR severity.  
9. TEE offers higher spatial resolution of mitralâ€‘leaflet pathology, whereas CMR precisely quantifies regurgitant volume and LV remodeling.  
10. Staging integrates lesion severity, ventricular size/function, and symptoms; progression triggers more frequent imaging or intervention.  
11. Mild AS progresses slowly; infrequent imaging safely monitors for acceleration.  
12. Moderate AS may progress more rapidly; biennial or annual imaging detects transition to severe disease.  
13. Close surveillance of severe AS permits timely valve intervention before symptom onset or LV dysfunction.  
14. AR severity criteria include venaâ€‘contracta width, EROA, regurgitant volume, and regurgitant fraction; LV endâ€‘systolic dimension and ejection fraction guide surgical timing.  
15. In MS, diastolic pressure halfâ€‘time correlates with valve area; rising pulmonaryâ€‘artery systolic pressure signals hemodynamic burden.  
16. LV endâ€‘systolic dimensionâ€¯>â€¯40â€¯mm or ejection fractionâ€¯<â€¯60â€¯% in severe MR prompts earlier surgical referral even if the patient is asymptomatic.

#### ðŸ”· Tags
#Cardiology #ValvularHeartDisease #MitralRegurgitation #Surveillance #Echocardiography #ValveStaging #AorticStenosis #AorticRegurgitation #MitralStenosis

#### ðŸ“™ Reference
OttoÂ CM, NishimuraÂ RA, BonowÂ RO, etâ€¯al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease. *JÂ AmÂ CollÂ Cardiol*. 2021;77:e25â€“e197. doi:10.1016/j.jacc.2020.11.018Â (PMIDÂ 33342586)

---

### ðŸ–¼ï¸ Supplemental Figures and Videos

<figure>
  <img src="Echocardiograms Demonstrating Secondary Mitral Regurgitation in a Patient With Previous Inferior Myocardial Infarction.jpg" alt="Echocardiograms Demonstrating Secondary MR">
  <figcaption><strong>Echocardiograms Demonstrating Secondary Mitral Regurgitation in a Patient With Previous Inferior Myocardial Infarction</strong><br>
  Tethering of the posterior leaflet (arrow, left panel) is present as a result of the previous infarction and left ventricular remodeling. Mitral regurgitation (arrow, right panel) is evident on color flow imaging. Ao = ascending aorta; LA = left atrium; LV = left ventricle.</figcaption>
</figure>

<figure>
  <img src="Echocardiogram Showing Mitral Valve Prolapse.jpg" alt="Echocardiogram Showing Mitral Valve Prolapse">
  <figcaption><strong>Echocardiogram Showing Mitral Valve Prolapse</strong><br>
  Echocardiogram showing normal opening of the mitral valve (arrow, top left panel), which then prolapses into the left atrium during systole (arrows, top right panel). In a different patient with myxomatous degeneration, a flail portion of the posterior mitral valve is present (bottom panels); torn chordae are seen (arrowheads), leading to severe regurgitation seen on color flow imaging (arrow, bottom right panel). Ao = ascending aorta; LA = left atrium; LV = left ventricle.</figcaption>
</figure>

<figure>
  <video controls width="640">
    <source src="Rheumatic Mitral Regurgitation.mp4" type="video/mp4">
    Your browser does not support the video tag.
  </video>
  <figcaption><strong>Rheumatic Mitral Regurgitation</strong><br>
  The carotid pulse is normal. In the mitral area, S1 is obscured by a high-frequency grade 2 holosystolic murmur. The murmur begins with mitral closure and continues up to and through aortic closure.<br>
  This video is used with permission from the Michael S. Gordon Center for Simulation and Innovation in Medical Education, University of Miami Miller School of Medicine, Miami, Florida. https://gordoncenter.miami.edu</figcaption>
</figure>

<figure>
  <video controls width="640">
    <source src="Mitral Valve Prolapse.mp4" type="video/mp4">
    Your browser does not support the video tag.
  </video>
  <figcaption><strong>Mitral Valve Prolapse</strong><br>
  The carotid pulsation is normal. In the mitral area, midsystolic clicks and a high-frequency grade 3 late systolic crescendo murmur are present. Standing decreases venous return, reduces ventricular size, and results in earlier and more marked prolapse of the mitral valve leaflet, and earlier clicks and murmur.<br>
  This video is used with permission from the Michael S. Gordon Center for Simulation and Innovation in Medical Education, University of Miami Miller School of Medicine, Miami, Florida. https://gordoncenter.miami.edu</figcaption>
</figure>

### ðŸ“Š Supplemental Table

<table>
  <caption><strong>Serial Evaluation of Asymptomatic Patients With Left-Sided Valvular Conditions</strong></caption>
  <thead>
    <tr>
      <th>Condition</th>
      <th>Factors Considered</th>
      <th>VHD Stage</th>
      <th>Lesion Severity</th>
      <th>Frequency of Evaluation</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td rowspan="4"><strong>Aortic Stenosis</strong></td>
      <td rowspan="4">Stenosis severity; rate of progression; LV systolic function; ascending aorta dilation if associated with bicuspid aortic valve</td>
      <td>A</td>
      <td>At risk (V<sub>max</sub> &lt;2 m/s)</td>
      <td>â€”</td>
    </tr>
    <tr>
      <td>B</td>
      <td>Mild (V<sub>max</sub> 2.0â€“2.9 m/s or mean gradient &lt;20 mm Hg)</td>
      <td>Clinical evaluation yearly; echo every 3â€“5 y</td>
    </tr>
    <tr>
      <td>B</td>
      <td>Moderate (V<sub>max</sub> 3.0â€“3.9 m/s or mean gradient 20â€“39 mm Hg)</td>
      <td>Clinical evaluation yearly; echo every 1â€“2 y</td>
    </tr>
    <tr>
      <td>C1</td>
      <td>Severe (V<sub>max</sub> â‰¥4 m/s or mean gradient â‰¥40 mm Hg, AVA typically â‰¤1.0 cmÂ²)<br>Very severe (V<sub>max</sub> â‰¥5 m/s or mean gradient â‰¥60 mm Hg)</td>
      <td>Clinical evaluation yearly; echo every 6â€“12 mo</td>
    </tr>
    <tr>
      <td rowspan="3"><strong>Aortic Regurgitation</strong></td>
      <td rowspan="3">Regurgitation severity; rate of progression; LV ejection fraction; LV chamber size; ascending aorta dilation if bicuspid aortic valve</td>
      <td>B</td>
      <td>Mild (VC &lt;0.3 cm, ERO &lt;0.10 cmÂ², RV &lt;30 mL/beat, RF &lt;30%); normal EF</td>
      <td>Clinical evaluation yearly; echo every 3â€“5 y</td>
    </tr>
    <tr>
      <td>B</td>
      <td>Moderate (VC 0.3â€“0.6 cm, ERO 0.10â€“0.29 cmÂ², RV 30â€“59 mL/beat, RF 30%â€“49%)</td>
      <td>Clinical evaluation yearly; echo every 1â€“2 y</td>
    </tr>
    <tr>
      <td>C1</td>
      <td>Severe (VC &gt;0.6 cm, ERO â‰¥0.3 cmÂ², RV â‰¥60 mL/beat, RF â‰¥50%)</td>
      <td>Clinical evaluation every 6â€“12 mo; echo every 6â€“12 mo, more frequently for dilating LV</td>
    </tr>
    <tr>
      <td rowspan="2"><strong>Mitral Stenosis</strong></td>
      <td rowspan="2">Stenosis severity</td>
      <td>B</td>
      <td>Mild and moderate (MVA &gt;1.5 cmÂ², diastolic pressure half-time &lt;150 ms)</td>
      <td>Clinical evaluation yearly; echo every 3â€“5 y</td>
    </tr>
    <tr>
      <td>C1</td>
      <td>Severe (MVA 1.0â€“1.5 cmÂ², diastolic pressure half-time â‰¥150 ms or â‰¥220 ms with very severe stenosis, PASP &gt;50 mm Hg)</td>
      <td>Clinical evaluation yearly; echo every 1â€“2 y for MVA 1.0â€“1.5 cmÂ², every year for MVA &lt;1.0 cmÂ²</td>
    </tr>
    <tr>
      <td rowspan="3"><strong>Mitral Regurgitation</strong></td>
      <td rowspan="3">Regurgitation severity; rate of progression; EF; LV chamber size</td>
      <td>A</td>
      <td>Mild (VC &lt;0.3 cm, ERO &lt;0.2 cmÂ², RV &lt;30 mL/beat, RF &lt;30%)</td>
      <td>Clinical evaluation yearly; echo every 3â€“5 y</td>
    </tr>
    <tr>
      <td>B</td>
      <td>Moderate (VC &lt;0.7 cm, ERO 0.2â€“0.39 cmÂ², RV 30â€“59 mL/beat, RF 30%â€“49%)</td>
      <td>Clinical evaluation yearly; echo every 1â€“2 y</td>
    </tr>
    <tr>
      <td>C</td>
      <td>Severe (VC â‰¥0.7 cm, ERO â‰¥0.4 cmÂ², RV â‰¥60 mL/beat, RF â‰¥50%)</td>
      <td>Clinical evaluation every 6â€“12 mo; echo every 6â€“12 mo, more frequently for dilating LV</td>
    </tr>
  </tbody>
</table>

<p><em>
AVA = aortic valve area; echo = echocardiography; EF = ejection fraction; ERO = effective regurgitant orifice; LV = left ventricular; LVESD = left ventricular end-systolic dimension; MVA = mitral valve area; PASP = pulmonary artery systolic pressure; RF = regurgitant fraction; RV = regurgitant volume; VC = vena contracta width; VHD = valvular heart disease; V<sub>max</sub> = maximum aortic jet velocity.
</em></p>

<p><strong>Reference:</strong> Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease. J Am Coll Cardiol. 2021;77:e25â€“e197. <a href="https://doi.org/10.1016/j.jacc.2020.11.018">doi:10.1016/j.jacc.2020.11.018</a> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/33342586">33342586</a>
</p>